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RENAL DENERVATION FIELD
The release of unexpected results from the
SYMPLICITY HTN-3 (Renal Denervation in Patients
With Uncontrolled Hypertension) trial (1,2) has
stimulated continued lively discussions and many
hypotheses among believers and skeptics of renal
denervation (RDN) therapy as to the potential con-
founding factors leading to the unanticipated
outcome. Post hoc evaluation of the data has
furthered these discussions and provided important
insights. Hypotheses range from selection criteria of
hypertensive enrollees as “resistant to medication”
(3) and the Hawthorne effect (4), to catheter design
(5), operator inexperience, insufﬁcient amount
of therapy delivery (6), and/or imprecise location of
delivery, among others. Regardless, the impact of
the SYMPLICITY HTN-3 trial was notorious and
immediate. A large proportion of already skeptical
clinicians were sufﬁciently swayed, and referrals for
the therapy vanished, research suddenly dwindled,
scientists divided among believers and nonbelievers
along the RDN hypertension therapy fault line, and
several companies abruptly terminated their RDN
product line. Most other companies involved in
the RDN ﬁeld turned their focus on other pro-
ducts. Meanwhile, believers in RDN (i.e., clinicians,
researchers, scientist, engineers, investors, and
companies), and most importantly, hopeful patient
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PRE-CLINICAL SETTING
Although multiple models of hypertension are avail-
able to the research community (7,8), the normoten-
sive domestic swine has been the most utilized model
for the evaluation of RDN technologies (9). Although
clinical efﬁcacy markers such as blood pressure
reduction and inhibition of the resistance to antihy-
pertensive medication cannot be evaluated in this
model, the swine remains the preferred model to
evaluate acute and long-term effects of RDN due to
the similarities of swine vasculature to human.
Furthermore, study of the swine model has
AB BR E V I A T I O N S
AND ACRONYM S
NE = norepinephrine
RDN = renal denervation
RF = radiofrequency
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289contributed important information on the anatomy of
the periarterial sympathetic renal innervation. For
instance, awareness is emerging that renal nerves
reside closer to the arterial supply in the distal region
of the artery than in the proximal segment of the ar-
tery, where their position is also more unpredictable,
with possibly important implications for more distal
RF delivery.
RENAL DENERVATION SAFETY EVALUATION. Exten-
sive published reports support that the therapy may
be safely delivered through the renal artery without
long-term adverse effects (10,11). Initial thermal
injury to the arterial media (hyalinization) is followed
by uneventful healing through benign ﬁbrosis of the
wall with very minimal non-stenosing neointima
formation and rapid re-endothelialization (Figure 1).
Although rare occurrences of procedural complica-
tions have been noted (i.e., dissections caused by
guidewires during catheterization), there are virtually
no arterial adverse events reported in published
reports in the animal model related to the delivery of
radiofrequency (RF) ablation (no thrombosis, dissec-
tions, or aneurysm formations attributable to RF
energy delivery). Collateral damage to adjacent
anatomical structures (i.e., psoas muscle, ureter, in-
testine) have been observed in the swine model yet
have not been correlated to any clinical observation.
It is important to note that adjustments to wattage,
delivery time, and type of electrodes have largely
eliminated these ﬁndings in pre-clinical studies. In
essence, the swine pre-clinical model not only
demonstrated the safety of RF RDN, but alsoFIGURE 1 Normal and RF-Treated Renal Artery Wall and Media
Representative images of a normal renal artery wall and media (left ima
Displaying the similar architecture the arterial wall and media of a renal a
media (right image; solid double-headed arrow) and necrosis of the su
denatured collagen; clear double-headed arrow).shepherded this therapy to current safer
clinical settings.
RDN EFFICACY EVALUATION. Delivery of RF
energy with single (10) or multiple (12) elec-
trode devices in a spiral fashion along the
length of the artery aims for complete abla-
tion of all renal nerves. Pre-clinical surrogates of
treatment effectiveness in the pre-clinical model
have included evidence of reduction of renal norepi-
nephrine (NE) and histological evidence of distal
nerve atrophy.
Although the acquisition and preparation of renal
samples for biochemistry vary among pre-clinical
studies (i.e., punch biopsy in the cranial, mid and
caudal portion of the anterior and posterior part of
the kidney, shaving of the anterior cortex, homoge-
nizing the entire kidney), it is understood to be a
time-sensitive evaluation. Therefore, minimizing the
time between euthanasia and sample collection for
snap freezing is crucial to maintaining accuracy and
consistency of the data. However, it has been
routinely demonstrated in intrastudy comparison
that the amount of NE of RF ablation–exposed ani-
mals is statistically signiﬁcantly lower than naive
controls (Figure 2). This NE level difference has been
established to be maintained over time. This effect
should be taken cautiously because it needs to be
considered that: 1) these models are normotensive
and potentially lacking the hyperexcitatory sympa-
thetic activity hypothesized as the rationale behind
resistant hypertensive patients (13); 2) there is vari-
ability in sample collection; and 3) and renal cortexge) displaying a normal arterial thickness (double-headed arrow).
rtery following radiofrequency (RF) treatment cycles with a hyalinized
rrounding connective tissue (amphophilic to basophilic staining of
FIGURE 2 Renal Parenchyma Norepinephrine Levels in Naive Control Subjects and
After RF Treatment
Representative renal parenchyma norepinephrine levels in naive controls compared with
samples following RF treatment at 7, 30, and 90 days in a normotensive porcine model.
There is a statistically signiﬁcant difference between all 3 time points (*) compared with
control.
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290NE has not been studied as a translatable counterpart
to the serum equivalent in human studies; there has
not been a study that demonstrates what is an
established baseline of NE in the porcine model or
one that compares baseline pre-clinical parameters
between all pre-clinical conditions of sampling,
breed, age, weight among other parameters that
could impact NE baseline levels.
Histological analysis of the nerve response both
acutely and at chronic follow-up post-RF treatment
reveals that ablated (necrotic) nerves become
remodeled through a progressive ﬁbrotic response
within and around the perineurium with evidence of
sclerotic and likely abortive nerve “sprouting”
proximal to and at the ablation site. This response
has been termed “neuromatous regeneration” and is
analogous to neuromas observed post-nerve ampu-
tations. This disorganized “regenerative” response
begins quite early in the process with evidence of
nerve tangles extending within the reactive peri-
neurium as early as 7 days following RF ablation.
This phenomenon is believed to be an attempt of the
injured nerve to restore nerve continuity and bypass
the ablated area. However, the chronic morpholog-
ical outcome is consistent with that of a mostly
nonfunctional (14) neuromatous response. However,
further research needs to be conducted to assess the
actual functional importance of these nerve tangles
and their long-term signiﬁcance. The evidence of
distal atrophy is to-date the most compelling
indication of effective nerve ablation (Figure 3).Nevertheless, the potential for functional regenera-
tion exists and was pointed to in the ﬁrst RDN
publication in Lancet in 2009 (15) with the state-
ment: “As shown in renal transplantation, renal
sympathetic efferent nerves might be able to regrow
after injury, indicating that the procedure could
have ﬁnite time limits in its physiological effects”
and restated in the SYMPLICITY HTN-2 trial: “One
problem is that sympathetic nerve regrowth might
mitigate the treatment effect” (16). This potential
should be further investigated.
NEW AREAS OF EXPLORATION
The release of the SYMPLICITY HTN-3 trial’s
“inconclusive” conclusions resulted in a dramatic
decrease in pre-clinical RDN research. However, this
technology holds untapped and yet-unresearched
potentials. The latest generation of devices allows
multiple simultaneous treatment delivery points
and/or aims for more distal delivery based on evi-
dence that renal nerves are closer to the arterial wall
in the distal part of the artery. Advancements in RDN
catheter engineering has lured the developers of
these technologies to explore new areas of potential
RF delivery (i.e., diabetes, arrhythmias, heart failure,
and so on [17–20]). Such territories include the pul-
monary arteries (pulmonary hypertension), carotid
arteries (hypertension), as well as arteries in the
gastrointestinal system (e.g., gastric, pancreatic ar-
teries). Although the clinical endpoint is different for
each anatomic location, the physiological lever is still
the interruption of the electrical signal between the
end organ and the central nervous system. In-
vestigators are also exploring new delivery modal-
ities (i.e., Ureter access, adventitial direct delivery
of RF energy) and alternate agents for denervation
(i.e., ultrasound, cryoablation, radiotherapy, chemi-
cal ablation).
A clear practical limitation of current denervation
techniques is the lack of any immediate functional or
visual feedback informing the operator that the
therapy was appropriately delivered. This limitation
has prompted some researchers to focus on technol-
ogies for accurate in vivo mapping of targeted nerves
and monitoring/probing of their functional response
and impairment upon RDN therapy.
OBJECTIVE IN CURRENT NEW
CLINICAL TRIAL DESIGN
Taking a lesson from past trials, 2 major players in the
ﬁeld of RDN, Boston Scientiﬁc and Medtronic, have
refocused objectives, and are now enrolling. Boston
Scientiﬁc is currently working to enroll 100 patients
FIGURE 3 Nerve Atrophy and Neuromatous Regeneration
To the left, representative histological images of nerve atrophy. Nerves distal to the location of delivery of the radiofrequency therapy typically
show histological evidence of atrophy (asterisks and solid arrows). To the right, representative image of neuromatous regeneration easily
identiﬁable with conventional stains (hematoxylin and eosin [H&E]) as increased ﬁbrous tissue response (blue dotted line) and nerve “sprouts”
(solid arrows) disrupting what was the original anatomy of the nerve (black dotted line).
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291in the REDUCE-HTN:REINFORCE trial, which is a
randomized, sham-controlled, multicenter study
designed to isolate and demonstrate the effects of the
Vessix renal denervation system (Boston Scientiﬁc,
Natick, Massachusetts). In this trial, patients will
undergo a 4-week washout period before enrollment
in which they will stop taking all hypertension med-
ications. The primary efﬁcacy assessment will be the
mean reduction of average 24-h ambulatory systolic
blood pressure 8 weeks post-randomization. This
design is intended to isolate the effect of RDN therapy
removed from the confounding effects of continued
antihypertensive medication.
Concurrently, Medtronic has designed the next
step in the evaluation of this therapy. The SPYRAL
HTN Global Clinical Trial Program consists of a
phase approach to determine the effects of renal
denervation in patients or those whose hypertension
has been difﬁcult to manage. The ﬁrst phase will
consist of 2 parallel studies, the SPYRAL HTN-OFF
MED (NCT02439749) and SPYRAL HTN-ON MED
(NCT02439775) trials. These studies are of a ran-
domized (1:1 renal denervation/sham-control group),
multicenter design aiming to enroll 120 and 100 pa-
tients, respectively (21–23). The SPYRAL HTN-OFF
MED study intends to demonstrate the real effect of
renal denervation in hypertensive patients without
additional hypertension treatment. The study design
will use a washout period of 4 weeks before
randomization, following the patients up to 12
months. The SPYRAL HTN-ON MED study is designed
to evaluate the application of renal denervation in aclinical practice setting in which the pharmacological
management of patients is required. In this case, the
enrolled patients will be subject to 3 standardized
medications. Both studies will be performed using
the third-generation Symplicity Spyral renal dener-
vation catheter (Medtronic, Dublin, Ireland). The
results of these 2 studies will determine the design of
the next phase in the SPYRAL HTN Global Clinical
Trial Program. By design, these studies intend to
avoid points that were considered potential culprits
of the results of the SYMPLICITY HTN-3 trial (i.e.,
they will avoid requirement of maximum drug
dose, measure drug prescription adherence, and
produce a theoretical decrease in comorbidities in
patients due to less severe hypertensive patient
enrollment) (24).
COULD THE FIELD OF RDN BENEFIT FROM
A NEW PERSPECTIVE, A NEW PROTOCOL?
The current paradigm for RF RDN is based on a single
RDN delivery. As far back as TCT 2010, Mazor et al.
(25) presented histological data demonstrating the
progressive decrease in larger nerves count and
increase in smaller nerves (interpreted as possible
evidence of atrophy and/or regeneration) post-
denervation with the Vessix balloon in a swine
model at long-term follow-up. This was an early
indication that nerve microanatomy is measurably
altered by RDN treatment. Furthermore, in the ﬁrst
reports of surgical sympathectomy, a pioneering
approach for the ablation of renal nerves, Smithwick
FIGURE 4 Blood Pressure Data Over a Period of 10 Years
Blood pressure data over a period of 10 years after splanchnicectomy presented by Dr. Reginald H. Smithwick in 1953. This schematic presents
the signiﬁcant blood pressure reduction following the surgical procedure with the lowest level at 2-year follow-up. Ten years later, a
steady progressive increase in blood pressure was observed. Although it never reached back to the initial blood pressure, these data suggest
that a compensatory process occurred over time despite the surgically removed renal nerves. Modiﬁed and adapted with permission from
Smithwick and Thompson (26).
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292and Thompson (26) presented the long-term
(10 years) follow-up blood pressure of one patient in
which the surgeon physically removed all the nerves
surrounding the renal artery. Subsequently, there
was a decrease in systolic blood pressure to 88
mm Hg 2 years post-surgery and a rebound to 132
mm Hg after 10 years (Figure 4) (26). Such ﬁndings
raise the question of the feasibility of permanent
“denervation” via a catheter-based approach
considering that surgical ablation can be followed by
a late rebound in blood pressure. Clearly the reasons
for such a long-term outcome could be multiple,
such as nerve regeneration, local renorenal adapta-
tion involving distal ganglia and alternate sympa-
thetic pathways, non-renal response, etc. Nerve
regeneration has been demonstrated post-RF RDN
therapy, and whereas microscopic morphology sug-
gests that the neuromatous tangles that appear in
the animal model would not yield complete func-
tional recovery, it is possible that some recovery
does occur over time. Perhaps the technology,
enrollment, and the operators are not the only fac-
tors for mitigated results. It remains possible that we
are delivering the therapy in an optimal manner but
are dismissing what the pre-clinical data have been
telling us since the initial studies, namely, through
the more recent understanding of the histological
response in the animal model, based on this under-
standing, should a new therapeutic paradigm be
considered?Since the initial evaluations of the effects of RF
delivery to the renal arteries in animal models, it has
been consistently demonstrated that the healing
response primarily entails an increase in ﬁbrous
tissue around and within the injured nerve. This
response begins early after treatment and is very
pronounced at the sites of direct and overwhelming
thermal injury. The resulting enlargement of the
perineurium is accompanied by regenerative sprout-
ing, resulting in a complete alteration of the normal
anatomical structure. This progressive neuromatous
response is consistently observed in the pre-clinical
setting regardless of the technology employed or
time point evaluated (at earlier time periods, special
stains are required). The nerve architecture following
nerve denervation is completely different than in the
naive nerve. The robust ﬁbrous response entraps
regenerative nerve bundles in the perineurium and
separates any residual nerve ﬁbers within the nerve
(endoneurium). Fibrous tissue characteristically lacks
the amount of hydration present in viable normal
tissue, resulting in a tissue that is potentially more
prone to subsequent thermal damage. This was
described by Gonzalez-Suarez et al. (27) in a compu-
tational modeling study in which ﬁbrous tissue
increased the intensity and extent of the energy
delivered by favoring ﬂux of electric current and
increasing the intensity of the electric ﬁeld. Further-
more, Liu et al. (28) characterized the “oven effect”
that ﬁbrous tissue produces as a distinguishing
FIGURE 5 Fibrous Septa Temperature Distribution and Fibrosis in a Normal and RF-Treated Nerve
On the left side of the image, we see the representative image of temperature distribution at steady state (t ¼ 8,000 s) for an intermediate (above) and high (below)
density ﬁbrous septa architecture in a 2-dimensional model of subcutaneous tissue and muscle subjected to a relatively long, constant, low-power radiofrequency
(RF) treatment. Solid line contours denote the extent of irreversible thermal damage (modiﬁed and adapted with permission from Gonzalez-Suarez et al. [27]). On the
right side of the image, we can observe a representative image of a normal nerve stained with H&E (left) and elastin trichrome (ET) (right). By contrast, below is a
representative image of a nerve subjected to RF ablation with an evident perineurial and endoneurial ﬁbrosis. The experiment by Gonzalez-Suarez et al. (27) suggests that
the increase of ﬁbrous tissue within and around the nerve may be an adjuvant in a more efﬁcacious delivery of RF energy in a subsequent therapy session.
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293feature in delivering RF energy. We, as well as other
laboratories, have demonstrated that immediately
following RF treatment, tissue collagen is severely
denatured (hyalinization), which is followed by
remodeling and gradual ﬁbrosis within 30 to 45 days
after the RF ablation (Figure 5) (14,29,30).
From these observations follows the hypothesis
that delivering a single course of RF RDN may not be
sufﬁcient to reach permanent long-term ablation.
We hypothesize that a judiciously timed second hit
may do better than consolidate an initial treatment
and would leverage the ﬁbrous tissue response to
maximize ablation in a territory rendered more sus-
ceptible to thermal injury. Considering that under
current technology, there is no immediate feedback
to the operator on the effectiveness of denervation
therapy delivery, and that there is pre-clinicalevidence of an attempt at nerve regrowth, it would
seems premature to label the therapy as “ineffective”
or a patient a “nonresponder” until the extent of RF
therapy may fully be ascertained and deemed inade-
quate or until a second course demonstrates that no
substantial gain is derived. Terumo and its Iberis
catheter (Terumo, Tokyo, Japan) have presented
“double ablation therapy” data in a pre-clinical model;
however, this design evaluated the safety of twice the
ablation time (120 s vs. 240 s) in a continuous fashion
without an intervening healing period rather than 2
separate treatments. The option of delivering RDN
ablation in a “2-step fashion” has not been investi-
gated to this day.
A single study indirectly alluded to this “one-two
punch theory” in a publication from Prochnau et al.
(31) in which they presented the data of 10 patients
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responders” to RF RDN and subsequently treated
with RDN cryoablation. These patients later demon-
strated a decrease in ofﬁce blood pressure at 3, 6, and
12 months (31). Our intent is not to suggest that one
technology is better than another (cryoablation vs.
radiofrequency), but rather to press forward the
concept that performing RDN by cryoablation in
nerves that were not naive may greatly potentiate
thermal injury and denervation effectiveness. The
cryoablation was delivered in already damaged and
ﬁbrotic nerves that we hypothesize would be more
susceptible to denervation therapies due to an in-
crease of ﬁbrous tissue in the surrounding perineu-
rium and within the nerve itself, the decrease of
hydration of the ﬁbrous tissue due to the neu-
romatous “sprouting,” and last but not least, the
likely injury to nerves previously spared. This
approach has not been evaluated in the clinical or
pre-clinical setting. The experimental models have
demonstrated that the ﬁrst RDN may be setting the
stage for a more powerful and more sweeping second
ablation hit.CONCLUSIONS
The ﬁeld of RDN was nearly halted upon release of
the SYMPLICITY HTN-3 clinical trial results. None-
theless, the scientiﬁc community continues to
explore new device designs, therapeutic areas, terri-
tories, and pathologies. The impending results from
on-going pivotal clinical trials will produce a new
panorama and clearer insights on the unmitigated
effects of the delivery of RF energy in hypertensive
patients. From the knowledge that ﬁbrous tissue is
more conductive than other tissue elements derives
the hypothesis that increased ﬁbrous response
around healing nerves may exacerbate the thermal
effect of RF energy. The hypothesis of a potentially
more effective and more durable “one-two punch”
delivery of RF RDN is a paradigm shift worth
investigating.
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